Violeta Razanskaite

Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme

L. Downey, Julia Wright, C. Underhill, 2017, Journal of Crohn's & colitis.

Heterogeneity in outcome assessment for inflammatory bowel disease in routine clinical practice: a mixed-methods study in a sample of English hospitals

P. Williamson, K. Bodger, C. Kallis, 2021, BMJ Open.

Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti‐TNF‐refractory Crohn’s disease

Philip Smith, K. Bodger, S. Dodd, 2020, Alimentary pharmacology & therapeutics.